Neuphoria Therapeutics Inc.(NEUP)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,448 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
NEUP Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Neuphoria Therapeutics Inc. (NEUP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NEUP at 31.6/100 on a 32-signal composite quality model, placing it at rank #2,448 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of NEUP by reported 13-F value include Lynx1 Capital Management, AdvisorShares Investments, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. NEUP trades on the Nasdaq exchange and files with the SEC under CIK 1191070. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NEUP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Neuphoria Therapeutics Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-505.1K
ROIC
Q1 2026
-16.5%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
+97.6% YoYOperating Income
+93.7% YoYEPS (Diluted)
+98.8% YoYTotal Assets
+3.4% YoYOp. Cash Flow
+100.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $15.6M | — | $22.0K -91.6% | $263.6K | — | $46.7K |
| Net Income | $-369.6K +97.6% | $-15.5M +27.5% | $-21.4M | — | — | — |
| Operating Income | $-1.1M +93.7% | $-17.9M +18.6% | $-22.0M | — | — | — |
| EPS (Diluted) | $-0.23 +98.8% | $-18.62 -93000.0% | $-0.02 | — | — | — |
| Total Assets | $28.6M +3.4% | $27.6M -3.2% | $28.6M -56.3% | $65.3M +20.4% | $54.3M | — |
| Operating Cash Flow | $77.2K +100.5% | $-14.7M -0.3% | $-14.6M | — | — | — |
Get alerted when NEUP's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Neuphoria Therapeutics Inc. including:
Top Institutional Holders of NEUP
Lynx1 Capital Management LP
$3.8M875,328 shAdvisorShares Investments LLC
$1.1M252,909 shVANGUARD CAPITAL MANAGEMENT LLC
$758.1K173,488 shShay Capital LLC
$680.9K155,822 shBALYASNY ASSET MANAGEMENT L.P.
$621.5K142,228 shCITADEL ADVISORS LLC
$317.1K72,559 shGEODE CAPITAL MANAGEMENT, LLC
$216.4K49,516 shIkarian Capital, LLC
$207.3K47,443 shVANGUARD FIDUCIARY TRUST CO
$147.7K33,806 shADAR1 Capital Management, LLC
$131.1K30,000 sh
| Fund | Value | Shares |
|---|---|---|
| Lynx1 Capital Management LP | $3.8M | 875,328 |
| AdvisorShares Investments LLC | $1.1M | 252,909 |
| VANGUARD CAPITAL MANAGEMENT LLC | $758.1K | 173,488 |
| Shay Capital LLC | $680.9K | 155,822 |
| BALYASNY ASSET MANAGEMENT L.P. | $621.5K | 142,228 |
| CITADEL ADVISORS LLC | $317.1K | 72,559 |
| GEODE CAPITAL MANAGEMENT, LLC | $216.4K | 49,516 |
| Ikarian Capital, LLC | $207.3K | 47,443 |
| VANGUARD FIDUCIARY TRUST CO | $147.7K | 33,806 |
| ADAR1 Capital Management, LLC | $131.1K | 30,000 |
More Healthcare Companies
View all Healthcare →Put NEUP on your watchlist
Track score changes the day Neuphoria Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NEUP a good stock to buy?
13F Pro's AI-powered analysis of Neuphoria Therapeutics Inc. (NEUP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NEUP are available on the NEUP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NEUP is classified as a small company.
Which hedge funds own NEUP?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NEUP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Neuphoria Therapeutics Inc.'s investment landscape.